Julian Winocour
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Julian Winocour has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Christodoulos Kaoutzanis
Division of Plastic and Reconstructive Surgery, University of Colorado Anschutz Medical Campus
2 shared publications - David Woodbridge Mathes
Division of Plastic and Reconstructive Surgery, University of Colorado Anschutz Medical Campus
2 shared publications - Katie G. Egan
Division of Plastic and Reconstructive Surgery, Department of Surgery University of Colorado Anschutz Medical Campus Aurora Colorado USA
2 shared publications - Alec S. McCranie
Division of Plastic and Reconstructive Surgery, Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
1 shared publication - Bilal F. Hamzeh
Department of Pediatric Plastic and Reconstructive Surgery, Children’s Hospital Colorado
1 shared publication - Carson Keeter
Department of Orthopedics University of Colorado School of Medicine Aurora Colorado U.S.A.
1 shared publication
Latest Publications
- Open Access
- 28 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (13) , 5042
Effects of GLP-1 Receptor Agonists on Breast Reconstruction Outcomes: A Large-Database Retrospective Study
Background/Objectives: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly prescribed for diabetes and weight loss, with many breast reconstruction candidates being prescribed these medications. However, perioperative risks remain unclear. This study evaluated the association between GLP-1RA use and postoperative complications in implant-based and autologous tissue breast reconstruction. Methods: A retrospective analysis of TriNetX identified patients undergoing implant-based or autologous tissue breast reconstruction. Preoperative GLP-1RA users were compared to matched controls. Patients were propensity score matched (1:1 and 1:3) for demographics and comorbidities including body-mass index and timing of reconstruction (delayed vs. immediate). Ninety-day outcomes were assessed using logistic regression. Results: Between 2014 and 2024, 57,987 patients were identified, of which 823 were GLP-1RA users. Of those users, 326 patients undergoing implant-based reconstruction and 51 patients undergoing autologous reconstruction were matched to controls. In implant-based cohorts, GLP-1RA use was associated with increased odds of implant failure (1:1 OR 1.70, 95% CI 1.18–2.45, p = 0.0046), wound healing complications (1:1 OR 1.90, p = 0.027), and higher readmission/ED utilization (1:1 OR 1.80, 95% CI 1.04–3.21, p = 0.040). No significant differences were observed for hematoma, seroma, or thromboembolism. In autologous reconstruction, GLP-1RA use was not associated with increased risks. Conclusions: GLP-1RA use is linked to higher rates of implant failure, wound healing complications, and readmission in implant-based breast reconstruction only. These findings highlight the need for risk stratification and counseling of GLP-1RA users undergoing implant-based procedures and for further research investigating the implications of perioperative use of these agents in plastic surgery.
- 28 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (13) , 5042
Open AccessEffects of GLP-1 Receptor Agonists on Breast Reconstruction Outcomes: A Large-Database Retrospective Study
Background/Objectives: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly prescribed for diabetes and weight loss, with many breast reconstruction candidates being prescribed these medications. However, perioperative risks remain unclear. This study evaluated the association between GLP-1RA use and postoperative complications in implant-based and autologous tissue breast reconstruction. Methods: A retrospective analysis of TriNetX identified patients undergoing implant-based or autologous tissue breast reconstruction. Preoperative GLP-1RA users were compared to matched controls. Patients were propensity score matched (1:1 and 1:3) for demographics and comorbidities including body-mass index and timing of reconstruction (delayed vs. immediate). Ninety-day outcomes were assessed using logistic regression. Results: Between 2014 and 2024, 57,987 patients were identified, of which 823 were GLP-1RA users. Of those users, 326 patients undergoing implant-based reconstruction and 51 patients undergoing autologous reconstruction were matched to controls. In implant-based cohorts, GLP-1RA use was associated with increased odds of implant failure (1:1 OR 1.70, 95% CI 1.18–2.45, p = 0.0046), wound healing complications (1:1 OR 1.90, p = 0.027), and higher readmission/ED utilization (1:1 OR 1.80, 95% CI 1.04–3.21, p = 0.040). No significant differences were observed for hematoma, seroma, or thromboembolism. In autologous reconstruction, GLP-1RA use was not associated with increased risks. Conclusions: GLP-1RA use is linked to higher rates of implant failure, wound healing complications, and readmission in implant-based breast reconstruction only. These findings highlight the need for risk stratification and counseling of GLP-1RA users undergoing implant-based procedures and for further research investigating the implications of perioperative use of these agents in plastic surgery.
- Open Access
- 28 April 2025
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 15 (5) , 178
A Scoping Review of Precision Medicine in Breast Reconstruction (2011–2025)
Background: Personalization of medical care is a significant topic of interest. Precision medicine denotes customized medical treatments based on individual genetic, molecular, and/or biomarker data. We conducted a scoping review to identify studies exploring precision medicine in breast reconstruction. Objectives: (1) To map the existing literature, (2) to identify key concepts, and (3) to discuss current and future clinical implications of precision medicine in breast reconstruction. Eligibility criteria: Indexed journal articles (primary research studies) relating to precision medicine in breast reconstruction written in the English language. Sources of evidence: Medline (via Pubmed), Web of Science, and the Cochrane Library. Charting methods: Data charting of selected studies was performed independently by two reviewers using Microsoft Excel. Any discrepancies in data charting were addressed through inter-reviewer discussion and/or expert review. Results: Of 321 initial records, 9 studies that were published between 2011 and 2025 were included in the final review. Eight studies focused predominantly on genomics, and one study focused predominantly on targeted therapies. Genomic-based studies were frequently implemented to evaluate patient risk and inform clinical decision-making, while targeted therapies were used to optimize reconstructive outcomes through cell-based therapies. Conclusions: There is a limited but emerging body of literature on precision medicine in breast reconstruction. Genomic data are the driving force of precision medicine in breast reconstruction, and multiple potential avenues exist to achieve translational applications in the short-term period. Future efforts should focus on translating known genomic data into real-time clinical applications and investing in precision-based research for targeted therapies and regenerative medicine in breast reconstruction.
- 28 April 2025
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 15 (5) , 178
Open AccessA Scoping Review of Precision Medicine in Breast Reconstruction (2011–2025)
Background: Personalization of medical care is a significant topic of interest. Precision medicine denotes customized medical treatments based on individual genetic, molecular, and/or biomarker data. We conducted a scoping review to identify studies exploring precision medicine in breast reconstruction. Objectives: (1) To map the existing literature, (2) to identify key concepts, and (3) to discuss current and future clinical implications of precision medicine in breast reconstruction. Eligibility criteria: Indexed journal articles (primary research studies) relating to precision medicine in breast reconstruction written in the English language. Sources of evidence: Medline (via Pubmed), Web of Science, and the Cochrane Library. Charting methods: Data charting of selected studies was performed independently by two reviewers using Microsoft Excel. Any discrepancies in data charting were addressed through inter-reviewer discussion and/or expert review. Results: Of 321 initial records, 9 studies that were published between 2011 and 2025 were included in the final review. Eight studies focused predominantly on genomics, and one study focused predominantly on targeted therapies. Genomic-based studies were frequently implemented to evaluate patient risk and inform clinical decision-making, while targeted therapies were used to optimize reconstructive outcomes through cell-based therapies. Conclusions: There is a limited but emerging body of literature on precision medicine in breast reconstruction. Genomic data are the driving force of precision medicine in breast reconstruction, and multiple potential avenues exist to achieve translational applications in the short-term period. Future efforts should focus on translating known genomic data into real-time clinical applications and investing in precision-based research for targeted therapies and regenerative medicine in breast reconstruction.